NAPLES, Fla., Nov. 29, 2021 /PRNewswire/ - Enveric
Biosciences (NASDAQ: ENVB) ("Enveric" or the
"Company"), a patient-centric biotechnology company developing
next-generation mental health and oncology treatments by leveraging
psychedelic-derived molecules for the mind and synthetic
cannabinoids for the body, today announced that Dr.
Joseph Tucker, Chief Executive
Officer of Enveric Biosciences, will participate in the H.C.
Wainwright 2nd Annual Psychedelics Conference to be
hosted virtually on Monday, December 6,
2021.
Dr. Tucker's corporate presentation will be available on-demand
starting at 7:00 a.m. ET. Register to
attend here.
For more information about the conference, or to schedule a
one-on-one meeting with Enveric's management team, please contact
your appropriate representative directly, or send an email to H.C.
Wainwright at lk@hcwco.com, or KCSA Strategic Communications at
EnvericBio@kcsa.com.
About Enveric Biosciences
Enveric
Biosciences (NASDAQ: ENVB) is an innovative biotechnology
company developing a next-generation mental health and oncology
treatment clinical discovery platform, leveraging
psychedelic-derived molecules for the mind and synthetic
cannabinoids for the body. Enveric's robust pipeline supports drug
development from the clinic to commercialization for millions of
patients in need around the world suffering from conditions that
include cancer-related distress, PTSD and more. For more
information, please visit www.enveric.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/enveric-biosciences-to-participate-in-the-hc-wainwright-2nd-annual-psychedelics-virtual-conference-on-december-6th-301431941.html
SOURCE Enveric Biosciences